CFT1946 + Trametinib for Solid Tumors

This trial tests a new treatment called CFT1946 to assess its safety and tolerability in people with certain solid tumors. Researchers aim to determine the best dose of CFT1946 alone and in combination with other drugs like trametinib or cetuximab. Suitable candidates for this trial have solid tumors with a specific BRAF V600 mutation and have previously tried treatments, including a BRAF inhibitor. The trial seeks to assist those whose cancer has not responded to standard treatments. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial does not specify if you need to stop taking your current medications, but it does exclude those taking strong CYP3A4/5 inhibitors and inducers, including herbal medications. It's best to discuss your current medications with the trial team.

A previous study found CFT1946 to be safe and generally well-tolerated by patients, with most experiencing no serious side effects. Some research suggests that combining CFT1946 with trametinib might enhance its effectiveness, though this combination can sometimes cause skin-related side effects. Overall, evidence so far suggests that CFT1946 is safe for humans, but further research is needed for confirmation.¹²³⁴⁵

Researchers are excited about CFT1946 because it targets the V600 mutation seen in various solid tumors, offering a potentially more precise treatment approach. Unlike standard treatments like BRAF inhibitors, CFT1946 is designed to degrade mutant proteins that drive cancer growth, potentially overcoming resistance to existing therapies. When combined with trametinib, which inhibits a different part of the cancer cell growth pathway, CFT1946 might offer a more comprehensive attack on cancer cells, increasing effectiveness and reducing chances of recurrence. This combination could provide new hope for patients whose cancers have stopped responding to conventional treatments.

Research has shown that CFT1946 has potential in early studies for treating certain tumors with a specific genetic change called BRAF V600. It generally tolerated well and could break down the BRAF V600E mutation, which often promotes cancer growth. Early evidence suggests that CFT1946 can shrink tumors, indicating possible effectiveness.